Antimicrobial resistance from a One Health perspective in Zambia: a systematic review.

Avis A Nowbuth, Akwi W Asombang, Nkengeh N Tazinkeng, Opeoluwa Y Makinde, Lincoln R Sheets
Author Information
  1. Avis A Nowbuth: Lusaka Apex Medical University, Lusaka, Zambia. anyanowbuth@gmail.com. ORCID
  2. Akwi W Asombang: Pan-African Organization for Health, Education and Research, Manchester, USA. ORCID
  3. Nkengeh N Tazinkeng: Pan-African Organization for Health, Education and Research, Manchester, USA. ORCID
  4. Opeoluwa Y Makinde: Pan-African Organization for Health, Education and Research, Manchester, USA. ORCID
  5. Lincoln R Sheets: School of Medicine, University of Missouri-Columbia, Columbia, MO, USA. ORCID

Abstract

BACKGROUND: Antimicrobial resistance (AMR) is widely acknowledged as a global health problem, yet its extent is not well evaluated, especially in low-middle income countries. It is challenging to promote policies without focusing on healthcare systems at a local level, therefore a baseline assessment of the AMR occurrence is a priority. This study aimed to look at published papers relating to the availability of AMR data in Zambia as a means of establishing an overview of the situation, to help inform future decisions.
METHODS: PubMed, Cochrane Libraries, Medical Journal of Zambia and African Journals Online databases were searched from inception to April 2021 for articles published in English in accordance with the PRISMA guidelines. Retrieval and screening of article was done using a structured search protocol with strict inclusion/exclusion criteria.
RESULTS: A total of 716 articles were retrieved, of which 25 articles met inclusion criteria for final analysis. AMR data was not available for six of the ten provinces of Zambia. Twenty-one different isolates from the human health, animal health and environmental health sectors were tested against 36 antimicrobial agents, across 13 classes of antibiotics. All the studies showed a degree of resistance to more than one class of antimicrobials. Majority of the studies focused on antibiotics, with only three studies (12%) highlighting antiretroviral resistance. Antitubercular drugs were addressed in only five studies (20%). No studies focused on antifungals. The most common organisms tested, across all three sectors, were Staphylococcus aureus, with a diverse range of resistance patterns found; followed by Escherichia coli with a high resistance rate found to cephalosporins (24-100%) and fluoroquinolones (20-100%).
CONCLUSIONS: This review highlights three important findings. Firstly, AMR is understudied in Zambia. Secondly, the level of resistance to commonly prescribed antibiotics is significant across the human, animal, and environmental sectors. Thirdly, this review suggests that improved standardization of antimicrobial susceptibility testing in Zambia could help to better delineate AMR patterns, allow comparisons across different locations and tracking of AMR evolution over time.

Keywords

References

  1. PLoS One. 2019 Dec 23;14(12):e0226676 [PMID: 31869354]
  2. Pan Afr Med J. 2020 Feb 07;35:32 [PMID: 32499849]
  3. BMC Infect Dis. 2017 Feb 2;17(1):117 [PMID: 28152988]
  4. Trop Med Int Health. 2013 Nov;18(11):1386-91 [PMID: 24033538]
  5. Antibiotics (Basel). 2019 Oct 31;8(4): [PMID: 31683590]
  6. Pathog Glob Health. 2015;109(7):309-18 [PMID: 26343252]
  7. Front Microbiol. 2019 May 31;10:1114 [PMID: 31214130]
  8. Trop Med Int Health. 2015 Nov;20(11):1492-1500 [PMID: 26224169]
  9. J Clin Microbiol. 2015 Jan;53(1):262-72 [PMID: 25392358]
  10. PLoS One. 2020 Aug 17;15(8):e0236156 [PMID: 32804970]
  11. Antibiotics (Basel). 2019 Sep 19;8(3): [PMID: 31546812]
  12. Expert Rev Dermatol. 2010 Apr;5(2):183-195 [PMID: 20473345]
  13. Bull World Health Organ. 2008 Dec;86(12):929-38 [PMID: 19142293]
  14. Int J Environ Res Public Health. 2016 Dec 28;14(1): [PMID: 28036049]
  15. BMJ. 2018 Jan 30;360:k462 [PMID: 29382641]
  16. AIDS. 2020 Oct 1;34(12):1833-1842 [PMID: 32889853]
  17. Indian J Med Microbiol. 2010 Oct-Dec;28(4):277-80 [PMID: 20966554]
  18. BMC Infect Dis. 2017 Sep 22;17(1):640 [PMID: 28938874]
  19. AIDS. 2020 Nov 1;34(13):1965-1969 [PMID: 32694410]
  20. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  21. Burns. 2019 Jun;45(4):983-989 [PMID: 30595542]
  22. Comp Immunol Microbiol Infect Dis. 2014 Mar;37(2):123-30 [PMID: 24480623]
  23. Pediatr Infect Dis J. 2016 Jul;35(7):e191-8 [PMID: 27031259]
  24. BMC Infect Dis. 2017 Sep 11;17(1):616 [PMID: 28893183]
  25. Syst Rev. 2021 Mar 29;10(1):89 [PMID: 33781348]
  26. Antimicrob Resist Infect Control. 2021 Mar 31;10(1):63 [PMID: 33789754]
  27. Tuberc Res Treat. 2010;2010:938178 [PMID: 22567261]
  28. Med J Zambia. 2010;37(2):58-63 [PMID: 23170038]
  29. AIDS. 2017 Jul 17;31(11):1637-1639 [PMID: 28481772]
  30. Am J Primatol. 2012 Dec;74(12):1071-5 [PMID: 22907634]
  31. BMC Res Notes. 2017 Aug 10;10(1):378 [PMID: 28797299]
  32. Trop Med Infect Dis. 2019 Jan 29;4(1): [PMID: 30700019]
  33. Trop Med Int Health. 2000 Oct;5(10):692-5 [PMID: 11044263]
  34. Lancet. 2020 Mar 14;395(10227):871-877 [PMID: 32087820]
  35. BMC Infect Dis. 2019 Dec 30;19(1):1087 [PMID: 31888518]
  36. J Occup Med Toxicol. 2015 Sep 16;10:34 [PMID: 26380579]
  37. Int J Tuberc Lung Dis. 2007 Nov;11(11):1216-20 [PMID: 17958984]
  38. Trop Med Infect Dis. 2019 May 31;4(2): [PMID: 31159338]
  39. PLoS One. 2020 Jan 24;15(1):e0220274 [PMID: 31978098]
  40. Sci Rep. 2015 Jul 27;5:12439 [PMID: 26211388]

MeSH Term

Animals
Humans
Zambia
Drug Resistance, Bacterial
One Health
Antitubercular Agents
Anti-Retroviral Agents
Escherichia coli

Chemicals

Antitubercular Agents
Anti-Retroviral Agents

Word Cloud

Created with Highcharts 10.0.0resistanceAMRZambiastudieshealthacrossAntimicrobialarticlessectorsantibioticsthreereviewlevelpublisheddatahelpcriteriadifferenthumananimalenvironmentaltestedantimicrobialfocusedpatternsfoundOneHealthBACKGROUND:widelyacknowledgedglobalproblemyetextentwellevaluatedespeciallylow-middleincomecountrieschallengingpromotepolicieswithoutfocusinghealthcaresystemslocalthereforebaselineassessmentoccurrenceprioritystudyaimedlookpapersrelatingavailabilitymeansestablishingoverviewsituationinformfuturedecisionsMETHODS:PubMedCochraneLibrariesMedicalJournalAfricanJournalsOnlinedatabasessearchedinceptionApril2021EnglishaccordancePRISMAguidelinesRetrievalscreeningarticledoneusingstructuredsearchprotocolstrictinclusion/exclusionRESULTS:total716retrieved25metinclusionfinalanalysisavailablesixtenprovincesTwenty-oneisolates36agents13classesshoweddegreeoneclassantimicrobialsMajority12%highlightingantiretroviralAntituberculardrugsaddressedfive20%antifungalscommonorganismsStaphylococcusaureusdiverserangefollowedEscherichiacolihighratecephalosporins24-100%fluoroquinolones20-100%CONCLUSIONS:highlightsimportantfindingsFirstlyunderstudiedSecondlycommonlyprescribedsignificantThirdlysuggestsimprovedstandardizationsusceptibilitytestingbetterdelineateallowcomparisonslocationstrackingevolutiontimeperspectiveZambia:systematicReview

Similar Articles

Cited By